
Ria Health Raises Growth Capital to Accelerate Access to Patient-Driven AUD Treatment

2024 SV Therapeutics Impact & ESG Report
Read More

Alpheus Medical Announces Positive Phase 1/2 Trial Results for the Treatment of Recurrent High-Grade Gliomas

Data Presented at the American College of Chest Physicians Correlates Airway Remodeling with Positive Clinical Outcomes Utilizing the RejuvenAir® System

SpectraWAVE Announces $50M Series B Financing to Drive Commercial Expansion and Product Additions to the HyperVue™ Imaging System

Pulse Biosciences, Inc. Appoints Paul LaViolette to Its Board of Directors - Paul LaViolette to serve as Co-Chairman alongside Robert W. Duggan, adding 40 years of medical technology development, operating and leadership expertise

Spineology® Announces $25 Million Equity Financing – Funding to aid in acceleration of commercial growth, clinical education programs, and product development enhancements for highly-differentiated OptiMesh® implant portfolio –

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

Endotronix Receives FDA Premarket Approval of the Cordella™ PA Sensor System for the Treatment of Heart Failure

Merck signs $3bn deal for Kate Bingham-backed eye disease biotech
Read More

SV Health Investors-created EyeBio to be acquired by MSD for up to $3 billion

Nanopath Receives $4 Million in Grants from National Institutes of Health and National Science Foundation

QurAlis to Present Data That Show its Splice-Switching ASOs Restore UNC13A Function in ALS and Frontotemporal Dementia
SV investment has resulted in the approval of 24 novel therapeutics

SV Health Investors bolsters senior biotech team - appoints Nikola Trbovic as Managing Partner and hires Jamil Beg as Partner

Hightop Health adds industry veteran to Board of Directors - Seasoned CEO and McLean Hospital Board Chair joins Hightop’s executive leadership

Merck to Acquire Caraway Therapeutics, Inc.

EyeBio Announces Expansion of Series A to $130 Million, Advances Development of Restoret for Retinal Diseases

SV Health Investors partners with HIT Executives Dave Dyell and Marc Hirshfield to Lead Recapitalization of Innovative Consulting Group
SV News
- 20 April 2021Portfolio NewsMestag Therapeutics launches with seed financing of $11 million to develop therapeutics targeting activated fibroblast populations across inflammatory disease and cancer
- 15 April 2021Portfolio NewsSutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck
- 15 April 2021Portfolio NewsSitryx further strengthens leadership team with the appointment of Iain Kilty, Ph.D., as Chief Scientific Officer
- 15 April 2021Portfolio NewsAlchemab raises £60M ($82M) in Series A financing to advance novel platform for identifying disease-modifying antibody therapeutics
- 12 April 2021Portfolio NewsXilio Therapeutics Strengthens Management Team with R&D Leadership Appointments
- 7 April 2021Portfolio NewsArtios Pharma Announces Collaboration with Novartis to Create Next Generation DDR Cancer Therapies
- 7 April 2021SV NewsThe Dementia Discovery Fund Significantly Enhances its Neuroscience R&D Expertise to Support its Portfolio
- 3 April 2021SV NewsUK vaccine supremo Kate Bingham: ‘The bickering needs to stop’
- 30 March 2021Portfolio NewsPionyr Immunotherapeutics Collaborates with Lonza to Support their Oncology Product Development
- 22 March 2021Portfolio NewsEvidation Raises $153M to Scale Virtual Health Capabilities of Achievement™ Platform
- 18 March 2021Portfolio NewsWellspring Capital Management Recapitalizes HealthPRO Heritage
- 17 March 2021Portfolio NewsAmathus Therapeutics signs strategic collaboration with Merck to Develop Treatments for Neurodegenerative Diseases